Personalized Cell Therapy Market, By Cell Type (Lymphocytes, Mesenchymal Stem Cell, Hematopoietic Stem Cell, and Others), by Therapeutic Area (Cardiovascular Diseases, Neurological Disorders, Inflammatory Diseases, Diabetes, and Cancer), and by Region (No

Personalized Cell Therapy Market, By Cell Type (Lymphocytes, Mesenchymal Stem Cell, Hematopoietic Stem Cell, and Others), by Therapeutic Area (Cardiovascular Diseases, Neurological Disorders, Inflammatory Diseases, Diabetes, and Cancer), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

The patient-tailored therapies for the treatment of various diseases is known as personalized cell therapy. The personalized cell therapy is based on genomic profile, and disease prevalence/severity and the drug developed by this therapy target the patients, who matches the specific disease physiopathology and/or patient characteristics. The personalized cell therapy is mainly developed for the treatment of high unmet need disease such as cancer, autoimmune disease, cardiovascular, neurologic, and inflammatory disease. Personalized cell therapy have application in platelet transfusions, packed red cell transfusions, bone marrow transplantation, and organ transplantation.
Personalized Cell Therapy Market Dynamics
Personalized cell therapy aids in accurate diagnosis of the disease and active monitoring of the treatment response, and disease progression. This allows for early detection of diseases at molecular level and allows physician to prepare treatment regime for the specific patient requirement. This helps the patient to recover at a significant pace and also helps avoid any major side effects, as individualized cell therapy is based on patient’s genomics.
Introduction of innovative personalized cell therapy and large number of cell therapies in pipeline by key players is expected to boost the market growth over the forecast period. For instance, in August 2017, the University of Pennsylvania and Children’s Hospital of Philadelphia (CHOP) received the U.S. Food and Drug Administration (FDA) approval for its newly developed personalized cellular therapy indicated for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.
Key features of the study:
This report provides in-depth analysis of the global personalized cell therapy market, market size (US$ Mn), and compound annual growth rate (CAGR %) over the forecast period (2022 - 2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new technology launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
It profiles leading players in the global personalized cell therapy market based on the following parameters – company overview, financial performance, technology portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include Cytori Therapeutics Inc., Bellicum Pharmaceuticals, Inc., Saneron CCEL Therapeutics, Inc., MolMed S.p.A., Vericel Corporation, Novartis AG, Gilead Sciences, Inc., Celgene Corporation, Bluebird Bio, Inc. and Aurora Biopharma Inc.
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to future technology launches, governmental initiatives, technological upgradation, market expansion, and marketing tactics
The global personalized cell therapy market report caters to various stakeholders in this market, including investors, technology manufacturers, distributors, and suppliers for global personalized cell therapy market, research and consulting firms, new entrants, and financial analysts
Detailed Segmentation:
Global Personalized Cell Therapy Market, By Cell Type:
Lymphocytes
Mesenchymal Stem Cell
Hematopoietic Stem Cell
Others
Global Personalized Cell Therapy Market, By Therapeutic Area:
Cardiovascular Diseases
Neurological Disorders
Inflammatory Diseases
Diabetes
Cancer
Global Personalized Cell Therapy Market, By Region:
North America
North America Personalized Cell Therapy Market, By Cell Type:
Lymphocytes
Mesenchymal Stem Cell
Hematopoietic Stem Cell
Others
North America Personalized Cell Therapy Market, By Therapeutic Area:
Cardiovascular Diseases
Neurological Disorders
Inflammatory Diseases
Diabetes
Cancer
North America Personalized Cell Therapy Market, By Country:
U.S.
Canada
Europe
Europe Personalized Cell Therapy Market, By Cell Type:
Lymphocytes
Mesenchymal Stem Cell
Hematopoietic Stem Cell
Others
Europe Personalized Cell Therapy Market, By Therapeutic Area:
Cardiovascular Diseases
Neurological Disorders
Inflammatory Diseases
Diabetes
Cancer
Europe Personalized Cell Therapy Market, By Country:
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
Asia Pacific Personalized Cell Therapy Market, By Cell Type:
Lymphocytes
Mesenchymal Stem Cell
Hematopoietic Stem Cell
Others
Asia Pacific Personalized Cell Therapy Market, By Therapeutic Area:
Cardiovascular Diseases
Neurological Disorders
Inflammatory Diseases
Diabetes
Cancer
Asia Pacific Personalized Cell Therapy Market, By Country:
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Latin America
Latin America Personalized Cell Therapy Market, By Cell Type:
Lymphocytes
Mesenchymal Stem Cell
Hematopoietic Stem Cell
Others
Latin America Personalized Cell Therapy Market, By Therapeutic Area:
Cardiovascular Diseases
Neurological Disorders
Inflammatory Diseases
Diabetes
Cancer
Latin America Personalized Cell Therapy Market, By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Middle East
Middle East Personalized Cell Therapy Market, By Cell Type:
Lymphocytes
Mesenchymal Stem Cell
Hematopoietic Stem Cell
Others
Middle East Personalized Cell Therapy Market, By Therapeutic Area:
Cardiovascular Diseases
Neurological Disorders
Inflammatory Diseases
Diabetes
Cancer
Middle East Personalized Cell Therapy Market, By Country:
GCC
Israel
Rest of Middle East
Africa
Africa Personalized Cell Therapy Market, By Cell Type:
Lymphocytes
Mesenchymal Stem Cell
Hematopoietic Stem Cell
Others
Africa Personalized Cell Therapy Market, By Therapeutic Area:
Cardiovascular Diseases
Neurological Disorders
Inflammatory Diseases
Diabetes
Cancer
Africa Personalized Cell Therapy Market, By Country/Region:
North Africa
Central Africa
South Africa
Company Profiles
Cytori Therapeutics Inc. *
Company Overview
Product Portfolio
Strategies Presence
Key Developments
Bellicum Pharmaceuticals, Inc.
Saneron CCEL Therapeutics, Inc.
MolMed S.p.A.
Vericel Corporation
Novartis AG
Gilead Sciences, Inc.
Celgene Corporation
Bluebird Bio, Inc.
Aurora Biopharma Inc.
“*” marked represents similar segmentation in other categories in the respective section.